TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2216299

Group type: EXPERIMENTAL
Intervention: Idarubicin (IDA) 45 mg/m2 orally on 3 consecutive days every 28 days
Number of subjects: 63

Group type: COMPARATOR
Intervention: Doxorubicin (ADRIA) 75 (60) mg/m2 intravenously every 21 days
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: All patients (IDA and ADRIA)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Idarubicin (IDA)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Doxorubicin (ADRIA)
Number of subjects: 63
Study: 358756

Group type: EXPERIMENTAL
Intervention: Diazepam (intramuscular injections)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Barbital (oral route)
Number of subjects: 91
Study: 30844309

Group type: EXPERIMENTAL
Intervention: High Fiber White Rice (HFWR) diet
Number of subjects: 18

Group type: COMPARATOR
Intervention: Regular White Rice (RWR) diet
Number of subjects: 18
Study: 28860461

Group type: EXPERIMENTAL
Intervention: Mobile-phone-based smoking cessation intervention
Number of subjects: 0
Study: 26019183

Group type: EXPERIMENTAL
Intervention: Low-dose THC (2.9%) with alcohol
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: High-dose THC (6.7%) with alcohol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Low-dose THC (2.9%) without alcohol
Number of subjects: 32

Group type: COMPARATOR
Intervention: High-dose THC (6.7%) without alcohol
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Placebo with alcohol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo without alcohol
Number of subjects: 32
Study: 23530566

Group type: EXPERIMENTAL
Intervention: Thai traditional massage (2-hour session, twice a week for 4 weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control period (no massage)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Thai traditional massage (specific subgroup: postmenopausal women in middle and higher tertiles of age and lower and middle tertiles of height)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control period (specific subgroup)
Number of subjects: 48
Study: 21668961

Group type: EXPERIMENTAL
Intervention: Traditional exercise program including sit-ups (TEP) with psychosocial educational program (PSEP)
Number of subjects: 4325

Group type: COMPARATOR
Intervention: Traditional exercise program including sit-ups (TEP) without psychosocial educational program (PSEP)
Number of subjects: 4325

Group type: EXPERIMENTAL
Intervention: Core stabilization exercise program (CSEP) with psychosocial educational program (PSEP)
Number of subjects: 4325

Group type: COMPARATOR
Intervention: Core stabilization exercise program (CSEP) without psychosocial educational program (PSEP)
Number of subjects: 4325
Study: 19159408

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg daily) for 10 days
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (no further treatment)
Number of subjects: 91
Study: 16825288

Group type: COMPARATOR
Intervention: Low-dose amiodarone alone
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Low-dose amiodarone plus losartan
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Low-dose amiodarone plus perindopril
Number of subjects: 177
Study: 12476528

Group type: EXPERIMENTAL
Intervention: DMSO
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PPS
Number of subjects: 0

Group type: COMPARATOR
Intervention: BCG
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hyaluronic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sacral nerve root stimulation
Number of subjects: 0
Study: 10441849

Group type: EXPERIMENTAL
Intervention: haemocorrecting drugs (rheopolyglucin, euphyllin, aspirin, curantyl, trental)
Number of subjects: 36

Group type: COMPARATOR
Intervention: vasoactive and metabolic drugs (cavinton, complamin, actovegin)
Number of subjects: 36
Study: 7790793

Group type: EXPERIMENTAL
Intervention: High‐dose, motorized, continuous traction (35%-50% of total body weight)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham or low‐dose traction (0-20% of body weight)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High‐dose, motorized, continuous traction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham or low‐dose traction
Number of subjects: 0
Study: 2370347

Group type: EXPERIMENTAL
Intervention: 1.5 T MRI
Number of subjects: 28

Group type: COMPARATOR
Intervention: 0.5 T MRI
Number of subjects: 28
Study: 348308

Group type: EXPERIMENTAL
Intervention: Cis-dichlorodiammineplatinum(II) single dose of 100 mg/m2 iv every 3-4 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cis-dichlorodiammineplatinum(II) continuous 5-day infusion of 20 mg/m2/day at 4-week intervals
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cis-dichlorodiammineplatinum(II) (both schedules)
Number of subjects: 26
Study: 30057231

Group type: EXPERIMENTAL
Intervention: Prior CABG surgery (n=201)
Number of subjects: 591

Group type: COMPARATOR
Intervention: No prior CABG surgery (n=390)
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 591
Study: 27839599

Group type: EXPERIMENTAL
Intervention: Acrylic IOL with optic-haptic junction inferotemporally
Number of subjects: 305

Group type: COMPARATOR
Intervention: Acrylic IOL with optic-haptic junction vertically
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Silicone IOL implanted inferotemporally
Number of subjects: 305
Study: 25107947

Group type: EXPERIMENTAL
Intervention: ICD implantation with defibrillation (DF) testing
Number of subjects: 1077

Group type: COMPARATOR
Intervention: ICD implantation without defibrillation (DF) testing
Number of subjects: 1077
Study: 23973639

Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg/day (Group A)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg/day (Group B)
Number of subjects: 19
Study: 20558925

Group type: EXPERIMENTAL
Intervention: Culture-guided triple therapy
Number of subjects: 701

Group type: COMPARATOR
Intervention: Standard triple therapy
Number of subjects: 701
Study: 18942246

Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.125%) with epidural fentanyl (100 microg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ropivacaine (0.2%) with epidural fentanyl (100 microg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Levobupivacaine (0.125%) with epidural fentanyl (100 microg)
Number of subjects: 60
Study: 15888211

Group type: EXPERIMENTAL
Intervention: Naloxone (0.04 mg/kg, I.V.)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 14
Study: 12452221

Group type: EXPERIMENTAL
Intervention: Remifentanil (9 microg/kg/h)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Morphine (0.045 mg/kg/h plus a bolus dose of 0.025 mg/kg)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Midazolam (0.03 mg/kg/h)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 189
Study: 9883223

Group type: EXPERIMENTAL
Intervention: Transurethral alprostadil
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study: 7611964

Group type: EXPERIMENTAL
Intervention: Suction drain
Number of subjects: 0

Group type: COMPARATOR
Intervention: No suction drain
Number of subjects: 0
Study: 1971027

Group type: EXPERIMENTAL
Intervention: Terazosin (2-40 mg, once daily)
Number of subjects: 0
Study: 326493

Group type: EXPERIMENTAL
Intervention: Sodium meclofenamate (300 mg daily)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31266654

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5-mg/saxagliptin 2.5-mg/metformin 1000-mg XR FCDP
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10-mg/saxagliptin 5-mg/metformin 1000-mg XR FCDP
Number of subjects: 84

Group type: COMPARATOR
Intervention: Food effect on both FCDPs
Number of subjects: 84

Group type: COMPARATOR
Intervention: Female subjects
Number of subjects: 84

Group type: COMPARATOR
Intervention: Safety profile of FCDPs
Number of subjects: 84
Study: 28760287

Group type: EXPERIMENTAL
Intervention: Surgery-first approach
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional orthognathic surgery approach
Number of subjects: 30
Study: 26328526

Group type: EXPERIMENTAL
Intervention: Planned Caesarean Section (CS)
Number of subjects: 2570

Group type: COMPARATOR
Intervention: Planned Vaginal Birth (VB)
Number of subjects: 2570
Study: 24584741

Group type: EXPERIMENTAL
Intervention: 20% intralipid infusion
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Insulin infusion
Number of subjects: 25

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 25
Study: 22962859

Group type: EXPERIMENTAL
Intervention: Casual outfit
Number of subjects: 179

Group type: COMPARATOR
Intervention: Semiformal outfit
Number of subjects: 179

Group type: COMPARATOR
Intervention: Formal outfit
Number of subjects: 179

Group type: COMPARATOR
Intervention: Outfit (any type)
Number of subjects: 179
Study: 19192468

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 17300592

Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg daily
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg daily
Number of subjects: 463

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 463
Study: 15580175

Group type: EXPERIMENTAL
Intervention: 35% CO2 challenge in Panic Disorder patients
Number of subjects: 43

Group type: COMPARATOR
Intervention: 35% CO2 challenge in healthy volunteers
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 35% CO2 challenge in male PD patients
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 35% CO2 challenge
Number of subjects: 43
Study: 11234566

Group type: EXPERIMENTAL
Intervention: Ipsilateral arm swing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both arms reciprocally swinging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conditioning-testing intervals of 400, 500, and 600 msec during ipsilateral backward arm swing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Onset of ipsilateral arm forward swing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Walking
Number of subjects: 0
Study: 9612624

Group type: EXPERIMENTAL
Intervention: Translaryngeal tracheostomy (TLT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Percutaneous dilatational tracheostomy (PT)
Number of subjects: 50
Study: 7531852

Group type: EXPERIMENTAL
Intervention: Triazolam (0.1‐0.56 mg/70 kg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Diazepam (10‐32 mg/70 kg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Hydromorphone (1‐6 mg/70 kg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 30016133

Group type: COMPARATOR
Intervention: No diabetes/no foot ulcers (control)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Diabetes but no foot ulcers
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Diabetes and foot ulcers
Number of subjects: 150
Study: 26948856

Group type: EXPERIMENTAL
Intervention: 4 mg/day BUP (BUP4)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: 16 mg/day BUP (BUP16)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 302
Study: 25110280

Group type: COMPARATOR
Intervention: Canagliflozin 300 mg (Treatment B)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Canagliflozin 300 mg (Treatment C)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Canagliflozin 150 mg (Treatment D)
Number of subjects: 37
Study: 23778032

Group type: EXPERIMENTAL
Intervention: 1.2g/day of ω‐3 polyunsaturated fatty acids (PUFA) for 12 weeks
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 1.2g/day of ω‐3 polyunsaturated fatty acids (PUFA)
Number of subjects: 81
Study: 19200979

Group type: EXPERIMENTAL
Intervention: Ganirelix
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control (no ganirelix)
Number of subjects: 89
Study: 19675104

Group type: EXPERIMENTAL
Intervention: P + 60 mg/d iron (Fe)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Fe
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: MM with added iron
Number of subjects: 406

Group type: COMPARATOR
Intervention: P alone
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Fe and MM
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Fe with added MM
Number of subjects: 406
Study: 16144766

Group type: EXPERIMENTAL
Intervention: Sedentary women
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Women extensor work
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Women flexor work
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Landing from a jump
Number of subjects: 36
Study: 15240537

Group type: EXPERIMENTAL
Intervention: Conventional-dose anthracycline-based chemotherapy
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: High-dose anthracycline-based plus alkylating chemotherapy
Number of subjects: 739

Group type: COMPARATOR
Intervention: Not applicable (surgical or chemotherapy regimen and histological type)
Number of subjects: 739

Group type: COMPARATOR
Intervention: Not applicable (parameters predicting early failure)
Number of subjects: 739

Group type: COMPARATOR
Intervention: Not applicable (parameters predicting early death)
Number of subjects: 739

Group type: COMPARATOR
Intervention: Not applicable (independent predictors of early failure)
Number of subjects: 739

Group type: COMPARATOR
Intervention: Not applicable (predictive model for early failure and death)
Number of subjects: 739
Study: 11071027

Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost
Number of subjects: 29

Group type: COMPARATOR
Intervention: 0.50% timolol
Number of subjects: 29
Study: 9054819

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy administered within 2 hours of symptom onset
Number of subjects: 2708

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy administered after 4 to 6 hours of symptom onset
Number of subjects: 2708

Group type: COMPARATOR
Intervention: Thrombolytic therapy administered after 1 hour of arrival at hospital
Number of subjects: 2708
Study: 8346772

Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac 30 mg
Number of subjects: 71

Group type: COMPARATOR
Intervention: Intramuscular diclofenac 75 mg
Number of subjects: 71
Study: 2427301

Group type: EXPERIMENTAL
Intervention: middle-molecular hydroxyethyl starch solution
Number of subjects: 30

Group type: COMPARATOR
Intervention: isotonic sodium chloride solution
Number of subjects: 30
Study: 30224909

Group type: EXPERIMENTAL
Intervention: Ambient light exposure at 5 lux
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ambient light exposure at 10 lux
Number of subjects: 60

Group type: COMPARATOR
Intervention: No ambient light exposure (control)
Number of subjects: 60
Study: 26724180

Group type: COMPARATOR
Intervention: Developmental surveillance at 100% of well-child visits (WCVs) for non-English, non-Spanish group
Number of subjects: 450

Group type: COMPARATOR
Intervention: Screened with a standardized developmental screening tool for non-English, non-Spanish group
Number of subjects: 450

Group type: COMPARATOR
Intervention: Referral for diagnostic developmental evaluation
Number of subjects: 450

Group type: COMPARATOR
Intervention: Developmental surveillance at 100% of WCVs for Spanish-speaking group
Number of subjects: 450

Group type: COMPARATOR
Intervention: Screened with a standardized developmental screening tool for Spanish-speaking group
Number of subjects: 450
Study: 24912459

Group type: EXPERIMENTAL
Intervention: Online parenting skills training (n=20)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Access to Internet resources on managing brain injury (n=17)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Low-income parenting skills group
Number of subjects: 37

Group type: COMPARATOR
Intervention: High-income Internet resource group
Number of subjects: 37
Study: 23248896

Group type: EXPERIMENTAL
Intervention: Multi-directional power toothbrush (Oral-B Professional Deep Sweep + SmartGuide TRICLEAN 5000)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Sonic control toothbrush (Philips Sonicare FlexCare)
Number of subjects: 128
Study: 20633268

Group type: EXPERIMENTAL
Intervention: High parental expressed emotion (EE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low parental warmth
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stress-related cortisol reactivity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High parental EE
Number of subjects: 0
Study: 18385186

Group type: EXPERIMENTAL
Intervention: Staff-oriented intervention (multi-faceted training for nurses about falls, risk factors, and environmental modifications)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 10
Study: 15798899

Group type: EXPERIMENTAL
Intervention: High case volume hospitals
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Medium case volume hospitals
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Low case volume hospitals
Number of subjects: 536
Study: 12193675

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 64

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 64

Group type: COMPARATOR
Intervention: Supine position with increased carbohydrate intake
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Prone position with increased carbohydrate intake
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Prone position during postprandial minutes 10-100
Number of subjects: 64
Study: 10071299

Group type: EXPERIMENTAL
Intervention: Testing for BRCA1 and BRCA2 offered free of charge
Number of subjects: 200
Study: 7564132

Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (Doxium) 3 x 500 mg orally for 2 years
Number of subjects: 74

Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (Doxium)
Number of subjects: 74
Study: 2201161

Group type: EXPERIMENTAL
Intervention: 1% sodium hyaluronate solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2% methylcellulose solution (placebo)
Number of subjects: 0
Study: 7299760

Group type: EXPERIMENTAL
Intervention: Levamisole (150 mg 3 days/week)
Number of subjects: 32

Group type: COMPARATOR
Intervention: D-penicillamine (250 mg increments at 2-3 monthly intervals)
Number of subjects: 32
Study: 30359616

Group type: EXPERIMENTAL
Intervention: Rapidly improving ARDS (defined by extubation or Pao2:Fio2 ratio > 300 on the first study day)
Number of subjects: 4361

Group type: EXPERIMENTAL
Intervention: Rapidly improving ARDS
Number of subjects: 4361

Group type: EXPERIMENTAL
Intervention: Predictive variables for rapidly improving ARDS
Number of subjects: 4361
Study: 27893550

Group type: EXPERIMENTAL
Intervention: 8 mg of dexamethasone applied to the masseter muscle after surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no corticosteroids)
Number of subjects: 30
Study: 26035702

Group type: EXPERIMENTAL
Intervention: nab‐PC (albumin-bound paclitaxel + carboplatin), N=265
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: nab‐PC (albumin-bound paclitaxel + carboplatin)
Number of subjects: 546

Group type: COMPARATOR
Intervention: sb‐PC (solvent‐based paclitaxel + carboplatin), N=281
Number of subjects: 546
Study: 23807094

Group type: COMPARATOR
Intervention: Placebo (no antibiotics)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Increase in sputum purulence
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: CRP concentration ≥ 40 mg/L
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Anthonisen criteria
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Anthonisen criteria + CRP level
Number of subjects: 152
Study: 21155632

Group type: EXPERIMENTAL
Intervention: MPH ER (up to 1 mg/kg per day)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: MPH ER
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 19951567

Group type: EXPERIMENTAL
Intervention: Twice daily human insulin mix 30/70
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Twice daily insulin lispro low mix 25
Number of subjects: 117

Group type: COMPARATOR
Intervention: Comparison of both treatments
Number of subjects: 117

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 117

Group type: COMPARATOR
Intervention: Human insulin mix 30/70
Number of subjects: 117

Group type: COMPARATOR
Intervention: Insulin lispro low mix 25
Number of subjects: 117
Study: 17715274

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 15605661

Group type: EXPERIMENTAL
Intervention: Endothelium-dependent dilatation (EDD) in patients with PAPS
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Endothelium-independent dilatation (EID) in patients with PAPS
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Endothelium-dependent dilatation (EDD) in patients with arterial involvement (17 patients)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Endothelium-dependent dilatation (EDD) in controls
Number of subjects: 31
Study: 11275673

Group type: EXPERIMENTAL
Intervention: Xylitol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Erythritol
Number of subjects: 30
Study: 9215204

Group type: EXPERIMENTAL
Intervention: Fetal acoustic stimulation test
Number of subjects: 577

Group type: COMPARATOR
Intervention: Mock test (control)
Number of subjects: 577
Study: 7679583

Group type: EXPERIMENTAL
Intervention: Captopril (12.5 mg three times a day after a 6.25 mg test dose, n = 32)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (20 mg three times a day, n = 31)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (n = 37)
Number of subjects: 100
Study: 3115916

Group type: EXPERIMENTAL
Intervention: Individualized educational program
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Group administered educational program
Number of subjects: 300

Group type: COMPARATOR
Intervention: Information/attention control
Number of subjects: 300

Group type: COMPARATOR
Intervention: Data-only control condition
Number of subjects: 300
Study: 30593463

Group type: EXPERIMENTAL
Intervention: Salbutamol (4 mg, three times a day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 28791362

Group type: EXPERIMENTAL
Intervention: COPD treatment group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Non-COPD group
Number of subjects: 60

Group type: COMPARATOR
Intervention: COPD control group
Number of subjects: 60
Study: 26401255

Group type: EXPERIMENTAL
Intervention: HIV protease inhibitors (HIV‐PIs) saquinavir and ritonavir (SQV+RIT)
Number of subjects: 0